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Abstract
Attachment of gp120 to CD4 during HIV-1 entry triggers structural rearrangement in gp120 enabling binding to an appropriate coreceptor. Following coreceptor engagement, additional conformational changes occur in the envelope (Env), resulting in fusion of virion and cell membranes. Catalysts with redox-isomerase activity, such as protein disulfide isomerase (PDI), facilitate Env conversion from its inactive to its fusion-competent conformation. We report here that anti-PDI agents effectively block CXCR4 Env-mediated fusion and spread of virus infection. Exogenously added PDI, in turn, can rescue fusion from this blockade. We further find that PDI facilitates thiol/disulfide rearrangement in gp120 during conformational change, whereas inhibition of this redox shuffling prevents gp41 from assuming the fusogenic six-helix bundle conformation. At the virus-cell contact site, gp120 induces assembly of PDI, CD4 and CXCR4 into a tetramolecular protein complex serving as a portal for viral entry. Our findings support the hypothesis that Env conformational change depends on a well-coordinated action of a tripartite system where PDI works in concert with the receptor and the coreceptor to effectively lower the activation energy barrier required for Env conformational rearrangement.
only.
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INTRODUCTION
HIV-1 entry requires attachment of the gp120 subunit of the viral envelope glycoprotein (Env) to its primary receptor, CD4. This interaction induces a structural rearrangement in Env exposing conserved regions of the gp120 subunit, thereby enabling binding to an appropriate coreceptor, primarily the chemokine receptors CXCR4 or CCR5 1, 2 . Engagement of gp120 to the coreceptor triggers conformational changes in the gp41 subunit leading to the formation of a sixhelix coiled-coil (trimer-of-hairpins) that involves exposure and subsequent insertion of the gp41 fusion peptide into the target cell membrane. This facilitates fusion of virion envelope with the host cell membrane and release of the viral capsid into the cytosol 3 .
Although the present model of HIV-1-mediated fusion and infection is thought to require only CD4 and a coreceptor, a reconstituted lipid bilayer system, which would incorporate only these components while excluding other cellular proteins, has not yet been developed to confirm this. Hence, it is conceivable that HIV-1 may rely on some additional catalyst to facilitate the conformational alterations in Env driving membrane fusion. Using inhibitors of thiol (-SH)/disulfide (-S-S-) exchange, Ryser et al. (1994) 4 showed inhibition of HIV-1 replication and postulated that catalysts with redox-isomerase activity assist in Env refolding during entry. Three more recent papers 5, 6, 7 provided additional support and novel insights supporting this hypothesis.
The candidate-protein proposed to drive the -SH/-S-S-exchange is cell-surface localized protein disulfide isomerase (PDI). PDI is considered a redox-isomerase, based on its ability to catalyze the reduction, formation and isomerization of disulfide bonds 8 . Although an endoplasmic reticulum-resident protein, PDI is commonly detected at the cell surface 9 . Given that PDI does not bear a transmembrane domain, its association with the plasma membrane occurs via noncovalent interactions with integral membrane proteins, lipids or glycans 10 .
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In addition to HIV-1, other animal viruses (baculovirus and vaccinia virus) have been shown to depend on the interchange of critical thiols and disulfides for successful entry. For example, thiol/disulfide interchange allows aggregation of the baculovirus fusion protein, gp64, into a fusogenic complex, which drives fusion of the viral envelope with the cell membrane 11 .
Vaccinia virus entry similarly depends on the reduction of critical disulfides in the core proteins, which disrupts viral structure and allows delivery of the viral core into the cytoplasm 12 . The catalyst driving the thiol/disulfide exchange in these viruses has not been elucidated. However, it is reasonable to postulate the involvement of a mechanism that modulates the exchange of protons between a cell-surface associated donor (PDI) and viral proteins. In addition to viral fusion, other protein-mediated membrane fusion reactions involving -SH/-S-S-interchange have been documented. Examples of such -SH/-S-S-dependent fusions include exocytosis, fertilization, microsome fusion and endocytosis 13 .
The present paper confirms the ability of PDI inhibitors to prevent Env-mediated fusion in an assay detecting the initial events leading to membrane fusion via the transfer of fluorescent dye from CD4 + /CXCR4 + cells to their Env-expressing fusion partners. Our data also corroborate that PDI antagonists inhibit cell-to-cell transmission of HIV infection as measured by a decrease in reverse transcriptase activity in supernatants from treated, infected cells. They further support the notion that disulfide bonds in gp120 are reduced upon attachment to CD4 on target cells, and that such reduction occurs prior to, or concomitant with, the coreceptor binding.
In addition to corroborating earlier results, the present paper provides several novel, previously unreported, findings: 1) It demonstrates both by immunocolocalization and immunoprecipitation the presence of a tetramolecular cell surface-associated complex comprised of PDI, gp120, CD4 and CXCR4; 2) It reveals a new function of gp120 which appears to be involved in recruiting the other three components that contribute to the tetramolecular complex, only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 5 as illustrated by the shift in immunocolocalization in the presence of gp120; 3) It shows that although PDI is recruited into the tetramolecular protein complex at the cell surface it is unlikely that this assembly takes place in GM1 lipid rafts; 4) This paper also provides evidence that treatment of target cells with the PDI inhibitor DTNB prevents gp41 from assuming the six-helix bundle fusogenic conformation believed necessary to drive fusion; 5) This work extends published data further to show that only PDI associated with the fusion partner expressing CD4/CXCR4 contributes to fusion.
EXPERIMENTAL PROCEDURES
Materials
Calcein AM was purchased from Molecular Probes (Eugene, OR), Immobilon-P filters from Millipore (Bedford, MA) and bovine liver PDI from Calbiochem (La Jolla, CA). Enhanced gp120 was produced as previously described 14 by infection of BS-C-1 cells with the recombinant vaccinia virus vPE 50 at 5PFU per cell.
Antibodies
Preparation of rabbit anti-HIV-1 gp41 serum directed against the N and C-terminal gp41
heptad repeats was described elsewhere 15 . The hybridoma producing the anti-gp41 MAb, Chessie for the duration of the experiment. Harvested supernatants were assayed for reverse transcriptase (RT) activity to monitor the progression of infection 20 . Curves shown reflect the best fits of sample means for duplicate wells that differed by not more than 15%.
Flow Cytometry
To study the effects of DTNB on CD4 or CXCR4, Sup T-1 cells (1-2x10 6 ) treated with 2.5 mM DTNB or PBS (control) were incubated either with 0.5 µg gp120 III B /1x10 6 cells (30 min, 22ºC) followed by anti-gp120 rabbit serum (15 min, 22ºC) and PE-conjugated anti-rabbit 
SDS-PAGE and Western blot analysis
SDS-PAGE and Western blot analysis were performed as described previously 21 . Briefly, proteins electrophoresed on 4-12% gradient Bis-Tris polyacrylamide gels (Invitrogen Corporation, Carlsbad, CA) were transferred to Immobilon-P filters, reacted with primary antibodies, then blots were washed and incubated with alkaline phosphatase conjugated goat anti-mouse or anti-rabbit IgG. After incubation with enhanced chemifluorescence substrate, dried blots were scanned on a Fuji Film Fluorescent Reader FLA-3000 at 473/520 nm excitation/emission wavelength with the Image Reader V 1.7 software package. Blots were quantified using Image Gauge V 3.45 (Fuji Film, Tokyo, Japan).
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Labeling of gp120
Cell-surface thiols were labeled with 3- ( To test whether PDI is associated with GM1 rafts, Sup T-1 cells were treated with gp120
in RPMI (0.5 µg/1x10 6 cells) followed by anti-PDI rabbit PAb and cholera toxin B subunit coupled to Alexa Fluor 594 (45 min, 4ºC). Further crosslinking with Cy2-coupled secondary antibodies was performed by incubation of cholera toxin-labeled cells for 10 min at 37ºC.
Cells were then fixed, attached to poly-L-lysine slides, mounted and visualized by confocal microscopy.
Co-immunoprecipitation
Anti CXCR4 MAb, 4G10, was allowed to interact with Protein G Sepharose beads (Amersham Pharmacia Biotech AB, Upsala, Sweden) for 1 h followed by covalent crosslinking 4°C, 1 h). The nuclear fraction was removed by centrifugation and 4G10/protein G beads were added to the supernatants for 14 h at 4°C. The beads were washed extensively with lysis buffer and proteins eluted by boiling in 4% LDS sample buffer, then analyzed for gp120, CD4 and PDI content by SDS-PAGE and immunoblotting with the corresponding polyclonal rabbit sera.
Flotation gradient experiments
The protocol for analysis of membrane rafts has been published elsewhere 22 . Briefly, to analyze PDI segregation into rafts, Sup T-1 cells ( 6x10 7 ) were treated with hypotonic buffer (10 mM Tris-HCl, pH 7.5, 4 mM EDTA and protease inhibitor cocktail) on ice. Post-nuclear supernatant was lysed in cold TNE buffer containing 0.25% TX-100, 25 mM Tris-HCl, 150 mM NaCl and 4 mM EDTA for 20 min on ice. Lysate was subsequently brought to 40% sucrose and overlaid with 30% followed by 5% sucrose in TNE buffer. Samples were subjected to flotation centrifugation at 46,000 rpm for 16 hrs at 4ºC using Beckman TLS-55 rotor. Ten fractions were recovered from the top of the gradient and analyzed by SDS-PAGE and Western blotting.
Transferrin receptor (TfR) was used as a non-raft marker, whereas p56 LCK (SrcK) was used as a raft-specific marker. Cellular cholesterol was depleted with 10 mM methyl-cyclodextrin (M CD) for 10 min at 37°C prior to flotation centrifugation, where indicated. In some instances, cells were treated with gp120 III B (0.5 µg/1x10 6 cells) before lysis.
For For To examine whether PDI from CHO-160 cells 24 contributes to fusion, Env + cells were treated with DTNB before incubation with CD4 + /CXCR4 + cells (Fig. 1C) . A minimal reduction in fusion occurred when Env + cells were pre-treated, whereas significant inhibition was observed when CD4 + /CXCR4 + cells were pre-treated with PDI inhibitor, indicating that fusion depends on the presence of functional PDI on the CD4/CXCR4-expressing target cell.
To determine whether the most efficacious PDI inhibitor, DTNB, alters gp120 binding to CD4 or CXCR4, we exposed CD4 + /CXCR4 + cells to 2.5 mM DTNB, which caused 88% fusion inhibition, and measured binding of soluble gp120 III B ( Fig. 2A) , Leu3A (CD4-specific MAb) (Fig. 2B ) and 12G5 (CXCR4-specific MAb) (Fig. 2C) (Fig. 2D) . Moreover, both cell-groups had comparable kinetics in eliminating Ca 2+ from the cytosol.
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Exogenous PDI can rescue cell-cell fusion
To confirm that PDI is a co-factor involved in viral entry, we designed a novel fusionrescue experiment whereby fusion was measured after the addition of exogenous PDI to cells previously treated with 2.5 mM DTNB. We found that PDI added at concentrations of 20 and 40 µg/ml following DTNB application and washout could restore Env-mediated fusion to levels comparable to those observed for the untreated controls (Fig. 3) . Together with the initial data showing fusion inhibition by specific PDI inhibitors (bacitracin and anti-PDI MAb), this finding provides strong evidence in support of PDI as a facilitator of HIV-1 entry. 
Functional PDI is necessary for successful viral infection
To confirm that PDI is essential for a spreading HIV-1 infection (i.e., cell-to-cell transmission), we examined the effect of PDI inhibitors DTNB, anti-PDI MAb and PAb on an acute infection of PM1 cells with CXCR4-tropic HIV-1 LAV . Addition of PDI inhibitors after completion of virus adsorption and maintaining them throughout the course of infection reduced the spread of virus as shown by a significant reduction in the peak RT activity relative to the controls (Fig. 4) . DTNB maintained in cell culture at 1 mM had no impact on cell viability (data only.
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Gp120 undergoes disulfide rearrangement after CD4 engagement
To determine whether gp120 undergoes disulfide rearrangement, releasing free thiols after engaging to CD4 and/or CXCR4, soluble recombinant gp120 III B was added to HOS-CD4 
Inhibition of gp120 redox shuffling prevents formation of the gp41 six-helix bundle
Using conformation-specific antibodies, we next attempted to determine how conformational changes leading to redox-isomerization in gp120 affect the activation (conformational modification) of gp41. An Ab specific for the six-helix bundle conformation of gp41, that exists following Env-CXCR4-binding but prior to fusion 15 , was used to immunoprecipitate gp41 from cells treated with DTNB (0-5 mM) (Fig. 6, panel 1) . The failure of only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From this antibody to immunoprecipitate gp41 in the presence of DTNB, which blocks PDI active sites (vicinal thiols), indicates that PDI-induced redox shuffling in gp120 is necessary to enable formation of the fusogenic six-helix bundle conformation of gp41. The intensity of the anti-actin controls (Fig. 6, panel 2) indicates no loss of material during immunoprecipitation or electrophoresis. 
PDI is associated with gp120/CD4/CXCR4 complex at the cell surface
To determine whether PDI co-localizes with CD4 and CXCR4 at the cell surface, we analyzed PDI distribution on the plasma membrane in the presence and absence of gp120 using scanning confocal microscopy. CD4 and CXCR4 exhibited significant co-localization as evident by the magenta-colored regions derived from the overlap of red CXCR4 and blue CD4 staining.
PDI (green), which had a consistent patchy, discontinuous distribution, showed no overt colocalization with CD4 or CXCR4 in the absence of gp120, evident by the absence of white regions in the image (Fig. 7A, left panel) . In contrast, in the presence of gp120, PDI was distributed largely in the CD4/CXCR4 regions, indicating considerable co-localization with these two markers. Furthermore, this shows that, even though PDI is a non-transmembrane domainbearing protein, it nevertheless segregates into very distinct membrane regions. Triple coonly.
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localization of PDI and receptors is indicated by the white, patchy regions on the cell resulting from green (PDI), red (CXCR4) and blue (CD4) overlap (Fig. 7A, right panel) . In addition, as more apparent in Fig 8A (right panel) , gp120 appears to induce PDI aggregation on the cell surface reflected by the larger green areas relative to those observed for PDI in cells not treated with gp120 (left panel).
Previously, two reports provided evidence for the existence of trimolecular protein complexes comprised of gp120, CD4 and an appropriate coreceptor 25, 26 . Using a similar approach, we sought to determine whether PDI could be associated with such a trimolecular protein complex as strong supportive biochemical evidence for the co-localization data obtained by confocal microscopy. Using the CXCR4-specific MAb, 4G10, we were able to precipitate complexes containing PDI from CD4+/CXCR4+ cells in the presence of gp120 (Fig. 7B ). This observation has not been reported previously in any other study and provides biochemical evidence that PDI, gp120, CD4 and CXCR4 associate together. Indeed, this corroborates a model whereby PDI is interacting with the gp120/CD4/CXCR4 complex to form a transient tetramolecular protein complex at the cell surface, which serves as a portal for viral entry.
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PDI fails to segregate in GM1 lipid rafts
Recent findings suggesting that CD4 associates with GM1 lipid rafts 27, 28 , coupled with the observations that disruption of cellular rafts inhibits viral entry and/or release 22, 29, 30 , have raised awareness of the potential role of lipid rafts in HIV-1 biology. Therefore, we sought to study PDI association with lipid rafts. First, we evaluated PDI co-localization with the cholera toxin B subunit, which binds the well-known raft marker, GM1, using confocal microscopy ( Fig.   8A ). We found that PDI does not co-localize with cholera toxin (as evident by the absence of yellow regions resulting from red-green overlap) in the presence or absence of gp120, which indicates a lack of PDI association with GM1 rafts. Second, we analyzed the association of PDI with rafts using equilibrium flotation gradient centrifugation, which relies on the insolubility of lipid-rafts in TX-100 at 4ºC ( Barbouche et al. (2003) 7 may be due to the use of SDF-1 to block CXCR4 in these latter studies, rather than cells devoid of the coreceptor.
Our current study provides evidence that treatment of target cells with the PDI inhibitor, DTNB, prevents gp41 from assuming the six-helix bundle conformation that drives fusion. This finding supports the concept that PDI-induced remodeling of gp120 is in some way transmitted to the gp41 subunit to activate its fusogenic properties, and could further explain the inhibitory mechanism of anti-PDI agents.
In addition to PDI, other oxido-reductases having cys-x-x-cys (CXXC) motifs that modulate thiol/disulfide exchange may also play a role in HIV-1 entry. For example, thioredoxin was suggested to have a role in HIV-1 entry because of its reductive action on the target membrane in experiments employing an arsenical compound known to block the vicinal thiols of the CXXC motifs of both PDI and thioredoxin 37 . Inasmuch as both proteins share a high level of functional and structural similarity in their catalytic domains, it is conceivable that both are involved in this restructuring process dependent on the redox exchange.
We observed that PDI associated with Env-expressing membranes does not contribute to fusion. This may reflect an inability of PDI to freely dissociate from its host membrane, suggesting that it has a restricted range of motion. It further shows that the topology of PDI (its spatial orientation relative to gp120, CD4 or CXCR4) is critical for its ability to facilitate membrane fusion. This is reminiscent of the function of v-SNARES and t-SNARES, which must be in an anti-parallel orientation to drive efficient membrane fusion during exocytosis 38 .
Importantly, we also observed that exogenous PDI can rescue cell-cell fusion that is inhibited by PDI antagonists. In this situation, the exogenous PDI could be exerting its effect by direct oxido-reductive activity on HIV Env. It is also possible that exogenous PDI is reducing 2-mercapto-5-nitrobenzoicacid (TNB) and liberating the catalytic thiol-reactive sites from only.
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Given that CD4 associates with GM1 lipid rafts 27, 28 , failure to detect PDI in GM1 rafts appears to contradict our confocal microscopy ( Fig. 7A ) and co-immunoprecipitation (Fig. 7B) data showing that PDI co-localizes and is associated with CD4 and CXCR4 in the presence of gp120. Despite the fact that other studies have challenged the role of lipid rafts as a place of viral entry 28, 40 , we recognize that results from our attempt to determine PDI localization and ascertain whether its action on gp120 takes place in these membrane domains is not sufficient to deny or support the significance of lipid rafts in HIV-1 entry. Still, several explanations may account for the observations in this study. First, it is possible that proteins weakly associated with the cell membrane, such as PDI, are difficult to detect in rafts using the TX-100 extraction-conditions. In this situation, detergent may induce the dissociation of weakly bound proteins from the cell membrane. This was shown for glycosyl-phosphatidylinositol-anchored placental alkaline phosphatase (PLAP) whose association with the TX-100 insoluble membrane fraction significantly increased upon Ab-induced lateral crosslinking stabilizing PLAP interactions with the membrane 41 . Secondly, it is possible that PDI associates with rafts that are not TX-100 resistant. In this regard, Roper et al. (2000) 42 reported selective extraction of proteins from membrane rafts based on the type of the detergent used. Third, the failure to detect PDI in GM1
rafts by scanning confocal microscopy may indicate that PDI segregates in a different type of rafts (e.g., GM3). There is increasing evidence suggesting that multiple cholesterol-based lipid rafts co-exist on the cell surface 42, 43 . However, we cannot exclude the possibility that our results indicate PDI is indeed associated with non-raft regions on the membrane.
There are several possible scenarios regarding HIV-1 entry and the temporal and physical only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From pattern of PDI association with the Env. First, assuming that PDI is associated with non-raft membrane domains, it is nevertheless possible that gp120 binding to CD4 occurs inside the GM1 lipid rafts. This interaction may initiate certain conformational changes in gp120, exposing previously buried disulfide bond-spanning gp120 regions. This, in turn, could facilitate the movement of Env-CD4 complexes out of GM1 rafts, perhaps to an area where PDI is located.
Our data, as well those of Gallina et al. (2002) 6 , suggest that PDI action takes place post CD4, but prior to or concomitant with CXCR4 Env binding. Thus, PDI-induced gp120 conformational change may indeed occur in non-raft domains. Alternatively, if one assumes that PDI exists in rafts that are distinct from the GM1 type, bringing PDI into contact with gp120 and CD4 would require clustering of PDI rafts with GM1 rafts. In this scenario, PDI-induced gp120 conformational change and fusion could conceivably take place at the interface of two different types of rafts or in the PDI-specific rafts. Nevertheless, in either scenario the association of PDI with Env and its cellular receptors should take place, and indeed we provide biochemical evidence with the specific detection of a tetramolecular protein complex comprised of PDI, gp120, CD4 and CXCR4.
Given that current anti-HIV-1 therapies are often associated with severe side effects, identification of drugs with novel mechanisms of action is imperative. A common problem in designing anti-HIV-1 therapies comes from the fact that selective pressure induces generation of drug-resistant virus strains, which can effectively escape therapy 44 . Escape mutants, however, are less likely to arise when the therapy targets sites which are critical for protein function, or when multiple sites are being affected. Inhibitors of redox-active enzymes can prevent Env conformational change by blocking thiol/disulfide reorganization, thereby inhibiting membrane fusion and subsequent entry. Virus attempts to escape or circumvent these agents would require replacement or alterations of the cysteines and disulfide bonds involved in Env conformational only.
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